33
Participants
Start Date
March 15, 2023
Primary Completion Date
February 10, 2025
Study Completion Date
February 10, 2025
Imvotamab
Administered intravenously
Placebo
0.9% sodium chloride administered intravenously
Accelacare - Salisbury, Salisbury
Omega Research MetroWest, Orlando
Arthritis and Rheumatic Disease Specialties, Aventura
Integral Rheumatology & Immunology Specialists, Plantation
Southwest Rheumatology Research, Mesquite
University of Colorado Hopsital - Anschutz Medical Campus, Aurora
Arizona Arthritis & Rheumatology Research, PLLC, Glendale
Triwest Research Associates, San Diego
East Bay Rheumatology Medical Group, San Leandro
Arizona Arthritis & Rheumatology Research, PLLC, Flagstaff
Centrum Reumatologii i Rehabilitacji NOVA REUMA, Bialystok
Nova Reuma Domyslawska i Rusilowicz Spólka Partnerska Lekarza Reumatologa i Fizjoterapeuty, Bialystok
Medicover Integrated Clinical Services (MCIS) Centrum Medyczne Bydgoszcz, Bydgoszcz
Niepubliczny Zakład Opieki Zdrowotnej Lecznica MAK-MED w Nadarzynie, Nadarzyn
Med Polonia Sp. z o. o. - Obornicka, Poznan
Medyczne Centrum Hetmanska, Poznan
Prywatna Praktyka Lekarska Prof. Dr Hab. Med. Paweł Hrycaj, Poznan
Reumedika s.c. Wiesława i Łukasz Porawscy, Poznan
Lead Sponsor
IGM Biosciences, Inc.
INDUSTRY